{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:28:40Z","timestamp":1780824520303,"version":"3.54.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115861"],"award-info":[{"award-number":["115861"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ebola virus disease (EVD) outbreaks are increasing, posing significant threats to affected communities. Effective outbreak management depends on protecting frontline health workers, a key focus of EVD vaccination strategies. IgG specific to the viral glycoprotein serves as the correlate of protection for recent vaccine licensures. Using advanced cellular and transcriptomic analyses, we examined B cell responses to the Ad26.ZEBOV, MVA-BN-Filo EVD vaccine. Our findings reveal robust plasma cell and lasting B cell memory responses post-vaccination. Machine-learning models trained on blood gene expression predicted antibody response magnitude. Notably, we identified a unique B cell receptor CDRH3 sequence post-vaccination resembling known <jats:italic>Orthoebolavirus zairense<\/jats:italic> (EBOV) glycoprotein-binding antibodies. Single-cell analyses further detailed changes in plasma cell frequency, subclass usage, and CDRH3 properties. These results highlight the predictive power of early immune responses, captured through systems immunology, in shaping vaccine-induced B cell immunity.<\/jats:p>","DOI":"10.1038\/s41467-025-61571-x","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:52:39Z","timestamp":1752137559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-9886","authenticated-orcid":false,"given":"Daniel","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1701-1390","authenticated-orcid":false,"given":"Elizabeth A.","family":"Clutterbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-0053","authenticated-orcid":false,"given":"Malick M.","family":"Gibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagida","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-9073","authenticated-orcid":false,"given":"Rebecca","family":"Makinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic F.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-719X","authenticated-orcid":false,"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"61571_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857\u2013866 (2015).","journal-title":"Lancet"},{"key":"61571_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","volume":"22","author":"MO Afolabi","year":"2022","unstructured":"Afolabi, M. O. et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect. Dis. 22, 110\u2013122 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"61571_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00564-z","volume":"7","author":"V Bockstal","year":"2022","unstructured":"Bockstal, V. et al. Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. NPJ Vaccines 7, 156 (2022).","journal-title":"NPJ Vaccines"},{"key":"61571_CR4","doi-asserted-by":"publisher","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","volume":"19","author":"Z Anywaine","year":"2022","unstructured":"Anywaine, Z. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Med. 19, e1003865 (2022).","journal-title":"PLoS Med."},{"key":"61571_CR5","doi-asserted-by":"crossref","unstructured":"Shukarev, G., Callendret, B., Luhn, K., Douoguih, M. & EBOVAC1 Consortium. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Hum. Vaccin Immunother. 13, 266\u2013270 (2017).","DOI":"10.1080\/21645515.2017.1264755"},{"key":"61571_CR6","doi-asserted-by":"publisher","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30476-X (2020).","DOI":"10.1016\/S1473-3099(20)30476-X"},{"key":"61571_CR7","doi-asserted-by":"publisher","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","volume":"18","author":"H Barry","year":"2021","unstructured":"Barry, H. et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 18, e1003813 (2021).","journal-title":"PLoS Med."},{"key":"61571_CR8","doi-asserted-by":"publisher","first-page":"e0196546","DOI":"10.1371\/journal.pone.0196546","volume":"13","author":"B Callendret","year":"2018","unstructured":"Callendret, B. et al. Correction: a prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS ONE 13, e0196546 (2018).","journal-title":"PLoS ONE"},{"key":"61571_CR9","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","volume":"2","author":"RF Grais","year":"2021","unstructured":"Grais, R. F. et al. Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2\/3 clinical trials. Lancet Microbe 2, e70\u2013e78 (2021).","journal-title":"Lancet Microbe"},{"key":"61571_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00261-9","volume":"5","author":"R Roozendaal","year":"2020","unstructured":"Roozendaal, R. et al. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. NPJ Vaccines 5, 112 (2020).","journal-title":"NPJ Vaccines"},{"key":"61571_CR11","doi-asserted-by":"publisher","first-page":"1215302","DOI":"10.3389\/fimmu.2023.1215302","volume":"14","author":"C McLean","year":"2023","unstructured":"McLean, C. et al. Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. Front. Immunol. 14, 1215302 (2023).","journal-title":"Front. Immunol."},{"key":"61571_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S1473-3099(24)00058-6","volume":"24","author":"Y Larivi\u00e8re","year":"2024","unstructured":"Larivi\u00e8re, Y. et al. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial. Lancet Infect. Dis. 24, 746\u2013759 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"61571_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nbt.3979","volume":"35","author":"DA Bolotin","year":"2017","unstructured":"Bolotin, D. A. et al. Antigen receptor repertoire profiling from RNA-seq data. Nat. Biotechnol. 35, 908\u2013911 (2017).","journal-title":"Nat. Biotechnol."},{"key":"61571_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-021-00657-1","volume":"22","author":"BJ Laidlaw","year":"2022","unstructured":"Laidlaw, B. J. & Ellebedy, A. H. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7\u201318 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"61571_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529\u2013542 (2014).","journal-title":"Immunity"},{"key":"61571_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/ni.2019","volume":"12","author":"SL Nutt","year":"2011","unstructured":"Nutt, S. L. & Tarlinton, D. M. Germinal center B and follicular helper T cells: siblings, cousins or just good friends?. Nat. Immunol. 12, 472\u2013477 (2011).","journal-title":"Nat. Immunol."},{"key":"61571_CR17","doi-asserted-by":"publisher","first-page":"100845","DOI":"10.1016\/j.xcrm.2022.100845","volume":"3","author":"WS Foster","year":"2022","unstructured":"Foster, W. S. et al. Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. Cell Rep. Med. 3, 100845 (2022).","journal-title":"Cell Rep. Med."},{"key":"61571_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/cei\/uxad013","volume":"211","author":"M Voysey","year":"2023","unstructured":"Voysey, M. et al. Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. Clin. Exp. Immunol. 211, 280\u2013287 (2023).","journal-title":"Clin. Exp. Immunol."},{"key":"61571_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s10875-023-01527-2","volume":"43","author":"HA Fryer","year":"2023","unstructured":"Fryer, H. A. et al. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize omicron BA.2 and BA.5 variants. J. Clin. Immunol. 43, 1506\u20131518 (2023).","journal-title":"J. Clin. Immunol."},{"key":"61571_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00724-9","volume":"8","author":"RGE Krause","year":"2023","unstructured":"Krause, R. G. E. et al. Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells. NPJ Vaccines 8, 119 (2023).","journal-title":"NPJ Vaccines"},{"key":"61571_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med. 384, 1824\u20131835 (2021).","journal-title":"N. Engl. J. Med."},{"key":"61571_CR22","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1016\/j.vaccine.2022.05.047","volume":"40","author":"J Sadoff","year":"2022","unstructured":"Sadoff, J. et al. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine 40, 4403\u20134411 (2022).","journal-title":"Vaccine"},{"key":"61571_CR23","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","volume":"110","author":"N Tatsis","year":"2007","unstructured":"Tatsis, N. et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110, 1916\u20131923 (2007).","journal-title":"Blood"},{"key":"61571_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.4049\/jimmunol.1502472","volume":"197","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Germinal center B cell and T follicular helper cell responses to viral vector and protein-in-adjuvant vaccines. J. Immunol. 197, 1242\u20131251 (2016).","journal-title":"J. Immunol."},{"key":"61571_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4049\/jimmunol.180.1.64","volume":"180","author":"IA Cockburn","year":"2008","unstructured":"Cockburn, I. A., Chakravarty, S., Overstreet, M. G., Garc\u00eda-Sastre, A. & Zavala, F. Memory CD8+ T cell responses expand when antigen presentation overcomes T cell self-regulation. J. Immunol. 180, 64\u201371 (2008).","journal-title":"J. Immunol."},{"key":"61571_CR26","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1128\/JVI.02407-10","volume":"85","author":"TW Geisbert","year":"2011","unstructured":"Geisbert, T. W. et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85, 4222\u20134233 (2011).","journal-title":"J. Virol."},{"key":"61571_CR27","doi-asserted-by":"publisher","first-page":"100207","DOI":"10.1016\/j.xcrm.2021.100207","volume":"2","author":"CM Nielsen","year":"2021","unstructured":"Nielsen, C. M. et al. Protein AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep. Med. 2, 100207 (2021).","journal-title":"Cell Rep. Med."},{"key":"61571_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/vaccines8010069","volume":"8","author":"EJ Anderson","year":"2020","unstructured":"Anderson, E. J. et al. Plasmablast, memory B cell, CD4+ T cell, and circulating follicular helper T cell responses to a non-replicating modified vaccinia ankara vaccine. Vaccines (Basel) 8, 69 (2020).","journal-title":"Vaccines (Basel)"},{"key":"61571_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","volume":"20","author":"M Akkaya","year":"2020","unstructured":"Akkaya, M., Kwak, K. & Pierce, S. K. B cell memory: building two walls of protection against pathogens. Nat. Rev. Immunol. 20, 229\u2013238 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"61571_CR30","doi-asserted-by":"publisher","first-page":"10522","DOI":"10.1128\/JVI.00450-10","volume":"84","author":"H Chen","year":"2010","unstructured":"Chen, H. et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J. Virol. 84, 10522\u201310532 (2010).","journal-title":"J. Virol."},{"key":"61571_CR31","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch, D. H. et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203\u20135209 (2011).","journal-title":"Vaccine"},{"key":"61571_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41590-023-01499-w","volume":"24","author":"NG Nu\u00f1ez","year":"2023","unstructured":"Nu\u00f1ez, N. G. et al. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nat. Immunol. 24, 941\u2013954 (2023).","journal-title":"Nat. Immunol."},{"key":"61571_CR33","doi-asserted-by":"publisher","first-page":"e100328","DOI":"10.1371\/journal.pone.0100328","volume":"9","author":"M Rakhmanov","year":"2014","unstructured":"Rakhmanov, M. et al. High levels of SOX5 decrease proliferative capacity of human B cells, but permit plasmablast differentiation. PLoS ONE 9, e100328 (2014).","journal-title":"PLoS ONE"},{"key":"61571_CR34","doi-asserted-by":"publisher","unstructured":"Khatri, I. et al. Longitudinal dynamics of human B-cell response at the single-cell level in response to Tdap vaccination. Vaccines (Basel) 9. https:\/\/doi.org\/10.3390\/vaccines9111352 (2021).","DOI":"10.3390\/vaccines9111352"},{"key":"61571_CR35","doi-asserted-by":"publisher","unstructured":"Zhu, H. et al. Molecular correlates of vaccine-induced protection against typhoid fever. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI169676 (2023).","DOI":"10.1172\/JCI169676"},{"key":"61571_CR36","doi-asserted-by":"publisher","first-page":"e9888","DOI":"10.15252\/msb.20209888","volume":"16","author":"D O\u2019Connor","year":"2020","unstructured":"O\u2019Connor, D. et al. Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. Mol. Syst. Biol. 16, e9888 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"61571_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","volume":"27","author":"P Rijal","year":"2019","unstructured":"Rijal, P. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172\u2013186.e177 (2019).","journal-title":"Cell Rep."},{"key":"61571_CR38","doi-asserted-by":"publisher","unstructured":"Galson, J. D. et al. BCR repertoire sequencing: different patterns of B cell activation after two Meningococcal vaccines. Immunol. Cell Biol. https:\/\/doi.org\/10.1038\/icb.2015.57 (2015).","DOI":"10.1038\/icb.2015.57"},{"key":"61571_CR39","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.ebiom.2015.11.034","volume":"2","author":"JD Galson","year":"2015","unstructured":"Galson, J. D. et al. Analysis of B cell repertoire dynamics following hepatitis B vaccination in humans, and enrichment of vaccine-specific antibody sequences. EBioMedicine 2, 2070\u20132079 (2015).","journal-title":"EBioMedicine"},{"key":"61571_CR40","doi-asserted-by":"publisher","first-page":"2268255","DOI":"10.1080\/19420862.2023.2268255","volume":"15","author":"O Mejias-Gomez","year":"2023","unstructured":"Mejias-Gomez, O. et al. A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies. MAbs 15, 2268255 (2023).","journal-title":"MAbs"},{"key":"61571_CR41","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.cell.2019.04.036","volume":"177","author":"CW Davis","year":"2019","unstructured":"Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus Infection. Cell 177, 1566\u20131582.e1517 (2019).","journal-title":"Cell"},{"key":"61571_CR42","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1182\/blood-2009-03-211052","volume":"114","author":"G Blanchard-Rohner","year":"2009","unstructured":"Blanchard-Rohner, G., Pulickal, A. S., Jol-van der Zijde, C. M., Snape, M. D. & Pollard, A. J. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 114, 4998\u20135002 (2009).","journal-title":"Blood"},{"key":"61571_CR43","doi-asserted-by":"publisher","unstructured":"Ellebedy, A. H. et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nat. Immunol. https:\/\/doi.org\/10.1038\/ni.3533 (2016).","DOI":"10.1038\/ni.3533"},{"key":"61571_CR44","doi-asserted-by":"publisher","first-page":"108684","DOI":"10.1016\/j.celrep.2020.108684","volume":"34","author":"HJ Sutton","year":"2021","unstructured":"Sutton, H. J. et al. Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. Cell Rep. 34, 108684 (2021).","journal-title":"Cell Rep."},{"key":"61571_CR45","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.4049\/jimmunol.1300712","volume":"190","author":"D Fern\u00e1ndez","year":"2013","unstructured":"Fern\u00e1ndez, D. et al. The proto-oncogene c-myc regulates antibody secretion and Ig class switch recombination. J. Immunol. 190, 6135\u20136144 (2013).","journal-title":"J. Immunol."},{"key":"61571_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1126\/science.276.5312.596","volume":"276","author":"Y Lin","year":"1997","unstructured":"Lin, Y., Wong, K. & Calame, K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276, 596\u2013599 (1997).","journal-title":"Science"},{"key":"61571_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41590-021-01088-9","volume":"23","author":"RC Brewer","year":"2022","unstructured":"Brewer, R. C. et al. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. Nat. Immunol. 23, 33\u201339 (2022).","journal-title":"Nat. Immunol."},{"key":"61571_CR48","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/vaccines10020136","volume":"10","author":"AM Diks","year":"2022","unstructured":"Diks, A. M. et al. Age and primary vaccination background influence the plasma cell response to pertussis booster vaccination. Vaccines (Basel) 10, 136 (2022).","journal-title":"Vaccines (Basel)"},{"key":"61571_CR49","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842.e816 (2020).","journal-title":"Cell"},{"key":"61571_CR50","doi-asserted-by":"publisher","first-page":"103956","DOI":"10.1016\/j.ebiom.2022.103956","volume":"78","author":"B Oriol-Tordera","year":"2022","unstructured":"Oriol-Tordera, B. et al. Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine 78, 103956 (2022).","journal-title":"EBioMedicine"},{"key":"61571_CR51","doi-asserted-by":"publisher","first-page":"e0274906","DOI":"10.1371\/journal.pone.0274906","volume":"17","author":"V Bockstal","year":"2022","unstructured":"Bockstal, V. et al. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: a randomized, controlled study. PLoS ONE 17, e0274906 (2022).","journal-title":"PLoS ONE"},{"key":"61571_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","volume":"226","author":"N Goldstein","year":"2022","unstructured":"Goldstein, N. et al. Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study. J. Infect. Dis. 226, 595\u2013607 (2022).","journal-title":"J. Infect. Dis."},{"key":"61571_CR53","doi-asserted-by":"publisher","first-page":"e1007390","DOI":"10.1371\/journal.ppat.1007390","volume":"14","author":"J Olejnik","year":"2018","unstructured":"Olejnik, J., Hume, A. J. & M\u00fchlberger, E. Toll-like receptor 4 in acute viral infection: too much of a good thing. PLoS Pathog. 14, e1007390 (2018).","journal-title":"PLoS Pathog."},{"key":"61571_CR54","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3389\/fmicb.2017.01571","volume":"8","author":"CY Lai","year":"2017","unstructured":"Lai, C. Y., Strange, D. P., Wong, T. A. S., Lehrer, A. T. & Verma, S. Ebola virus glycoprotein induces an innate immune response. Front. Microbiol. 8, 1571 (2017).","journal-title":"Front. Microbiol."},{"key":"61571_CR55","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00018-022-04582-x","volume":"79","author":"E Zhang","year":"2022","unstructured":"Zhang, E., Ma, Z. & Lu, M. Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases. Cell Mol. Life Sci. 79, 547 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"61571_CR56","doi-asserted-by":"publisher","first-page":"107323","DOI":"10.1016\/j.isci.2023.107323","volume":"26","author":"LJ Perez-Valencia","year":"2023","unstructured":"Perez-Valencia, L. J. et al. Ebola virus shed glycoprotein is toxic to human T, B, and natural killer lymphocytes. iScience 26, 107323 (2023).","journal-title":"iScience"},{"key":"61571_CR57","doi-asserted-by":"publisher","first-page":"e1006397","DOI":"10.1371\/journal.ppat.1006397","volume":"13","author":"M Iampietro","year":"2017","unstructured":"Iampietro, M. et al. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathog. 13, e1006397 (2017).","journal-title":"PLoS Pathog."},{"key":"61571_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.molimm.2010.09.008","volume":"48","author":"LM Ganley-Leal","year":"2010","unstructured":"Ganley-Leal, L. M., Liang, Y., Jagannathan-Bogdan, M., Farraye, F. A. & Nikolajczyk, B. S. Differential regulation of TLR4 expression in human B cells and monocytes. Mol. Immunol. 48, 82\u201388 (2010).","journal-title":"Mol. Immunol."},{"key":"61571_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09737","volume":"470","author":"SP Kasturi","year":"2011","unstructured":"Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543\u2013547 (2011).","journal-title":"Nature"},{"key":"61571_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29978-y","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Recycling of memory B cells between germinal center and lymph node subcapsular sinus supports affinity maturation to antigenic drift. Nat. Commun. 13, 2460 (2022).","journal-title":"Nat. Commun."},{"key":"61571_CR61","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.4049\/jimmunol.177.8.5337","volume":"177","author":"L Rui","year":"2006","unstructured":"Rui, L., Healy, J. I., Blasioli, J. & Goodnow, C. C. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation. J. Immunol. 177, 5337\u20135346 (2006).","journal-title":"J. Immunol."},{"key":"61571_CR62","doi-asserted-by":"publisher","first-page":"eabk0018","DOI":"10.1126\/sciimmunol.abk0018","volume":"7","author":"AE Denton","year":"2022","unstructured":"Denton, A. E. et al. Targeting TLR4 during vaccination boosts MAdCAM-1. Sci. Immunol. 7, eabk0018 (2022).","journal-title":"Sci. Immunol."},{"key":"61571_CR63","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood-2008-04-153544","volume":"113","author":"HE Mei","year":"2009","unstructured":"Mei, H. E. et al. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 113, 2461\u20132469 (2009).","journal-title":"Blood"},{"key":"61571_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2017.12.007","volume":"194","author":"RCM Rudolf-Oliveira","year":"2018","unstructured":"Rudolf-Oliveira, R. C. M. et al. Determination of normal expression patterns of CD86, CD210a, CD261, CD262, CD264, CD358, and CD361 in peripheral blood and bone marrow cells by flow cytometry. Immunol. Lett. 194, 44\u201355 (2018).","journal-title":"Immunol. Lett."},{"key":"61571_CR65","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","volume":"10","author":"L Khodadadi","year":"2019","unstructured":"Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The maintenance of memory plasma cells. Front. Immunol. 10, 721 (2019).","journal-title":"Front. Immunol."},{"key":"61571_CR66","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","volume":"53","author":"RA Elsner","year":"2020","unstructured":"Elsner, R. A. & Shlomchik, M. J. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 53, 1136\u20131150 (2020).","journal-title":"Immunity"},{"key":"61571_CR67","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.4049\/jimmunol.0803783","volume":"183","author":"FC Rau","year":"2009","unstructured":"Rau, F. C., Dieter, J., Luo, Z., Priest, S. O. & Baumgarth, N. B7-1\/2 (CD80\/CD86) direct signaling to B cells enhances IgG secretion. J. Immunol. 183, 7661\u20137671 (2009).","journal-title":"J. Immunol."},{"key":"61571_CR68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12865-020-00343-2","volume":"21","author":"S Axelsson","year":"2020","unstructured":"Axelsson, S. et al. A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex. BMC Immunol. 21, 14 (2020).","journal-title":"BMC Immunol."},{"key":"61571_CR69","doi-asserted-by":"publisher","unstructured":"Chelysheva, I., Pollard, A. J. & O\u2019Connor, D. RNA2HLA: HLA-based quality control of RNA-seq datasets. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab055 (2021).","DOI":"10.1093\/bib\/bbab055"},{"key":"61571_CR70","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"61571_CR71","unstructured":"R core team. R Foundation for Statistical Computing (Vienna, 2013)."},{"key":"61571_CR72","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/nar\/gks042","volume":"40","author":"DJ McCarthy","year":"2012","unstructured":"McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288\u20134297 (2012).","journal-title":"Nucleic Acids Res."},{"key":"61571_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"61571_CR74","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"61571_CR75","doi-asserted-by":"crossref","unstructured":"Weiner, J. tmod: Feature Set Enrichment Analysis for Metabolomics and Transcriptomics (CRAN, 2016).","DOI":"10.32614\/CRAN.package.tmod"},{"key":"61571_CR76","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"61571_CR77","doi-asserted-by":"publisher","first-page":"e1004503","DOI":"10.1371\/journal.pcbi.1004503","volume":"11","author":"M Shugay","year":"2015","unstructured":"Shugay, M. et al. VDJtools: unifying post-analysis of T cell receptor repertoires. PLoS Comput. Biol. 11, e1004503 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"61571_CR78","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bfgp\/elac044","volume":"22","author":"T Sundell","year":"2022","unstructured":"Sundell, T. et al. Single-cell RNA sequencing analyses: interference by the genes that encode the B-cell and T-cell receptors. Brief. Funct. Genomics 22, 263\u2013273 (2022).","journal-title":"Brief. Funct. Genomics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61571-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:30:46Z","timestamp":1752139846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61571"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61571-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.P. is chair of the UK Department of Health and Social Care\u2019s Joint Committee on Vaccination and Immunisation. A.J.P., S.B., E.A.C., K.A.S., R.M. and D.O.C. are contributors to intellectual property licensed by Oxford University Innovation to AstraZeneca. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6331"}}